Trial Designs and Outcomes in Dementia Therapeutic ResearchCRC Press, 2005 M11 23 - 324 pages Given the increased attention of clinicians, researchers, and the pharmaceutical industry to the management and treatment of dementia not only in the elderly but also in increasingly younger populations, the demands for effective evidence-based pharmaceutical control of dementia and quantitative assessment of outcomes have increased. From the first steps in the early 1960s to the controversial landmark paper of Summers and colleagues to the most recent trials, it is clear both that much progress has been made and that much remains to be done. This book is written to take stock of what is now usefully known and to speculate on directions for the future. |
Contents
Treatment Hypotheses | |
Clinical Trial Designs and Endpoint Selection | |
The Use of Qualitative Research | |
Inclusion and Exclusion Criteria | |
Structural Neuroimaging Outcomes | |
Guidelines for Randomised Clinical Studies in Parkinsons Disease with Dementia and Dementia with Lewy Bodies | |
Clinical Trials for Vascular Cognitive Impairment | |
Clinical Trials for Primary Prevention in Dementia | |
Clinical Trials for Memantine | |
Clinical Trials for Psychotropic Agents in Alzheimers Disease | |
Clinical Trials for Psychosocial Interventions Aimed at Caregivers of People with Dementia | |
Pharmacoeconomic Outcomes | |
Global Assessment Measures | |
Cognitive Outcomes | |
Functional Outcomes | |
Behavioural Outcomes | |
Quality of Life Outcomes | |
Caregiver Burden Outcomes | |
Executive Dysfunction in Dementia | |
Ethical Considerations in the Conduct of Clinical Trials for Alzheimers Disease | |
Designs for Trials when there is a Standard Therapy Superiority Equivalence NonInferiority | |
Conclusion Lessons from Clinical Trials in Dementia | |
Index | |
Other editions - View all
Trial Designs and Outcomes in Dementia Therapeutic Research Kenneth Rockwood,Serge Gauthier No preview available - 2006 |
Common terms and phrases
active ADAS-Cog Alzheimer Alzheimer’s disease analysis approach assessment associated attention behavioural benefit bodies brain burden caregivers cholinesterase Clin clinical trials clinicians cognitive compared comparison con considered controlled criteria decline Dement dementia depression detect diagnosis dis Disord donepezil drug early effect efficacy elderly et al ethical evaluation evidence Examination example executive factors findings function Geriatr global Health impairment important improvement increase individuals inhibitors International interventions interviews issues less Lewy mean measures medication memantine memory ment methods mild MMSE moderate Neurol Neurology observed outcome participants patients persons placebo placebo-controlled points population possible potential practice prevention progression Psychiatry randomised randomized recent reported response risk Rockwood sample Scale scores selection severe significant social specific stages strategies subjects suggested symptoms tests therapy tion treated treatment understanding validity vascular